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As one of the most frequent symptoms, measurement of fatigue is an issue of interest in Parkinson’s disease (PD). The fatigue
severity scale (FSS) is one of the recommended questionnaires for this purpose.The aim of our study was to evaluate psychometric
properties of the Persian version of the FSS (FSS-Per) to assess fatigue in PD patients. Ninety nondemented idiopathic Parkinson’s
disease (IPD) patients were consecutively recruited from an outpatient referral movement disorder clinic. In addition to the disease
severity scales, the FSS-Per was used for fatigue measurement. The internal consistency coefficient was larger than 0.8 for all of the
items with a total Cronbach’s alpha of 0.96 (95% CI: 0.95–0.97). The FSS-Per score correlated with the UPDRS score (𝑟 = 0.55,
𝑃 < 0.001) and the “Hoehn and Yahr” (HY) stage (𝑟 = 0.48, 𝑃 < 0.001). The total score of the FSS-Per significantly discriminated
IPD patients with more severe disability (HY stage > 2) versus those with less severe disease (HY stage ≤ 2) (AUC = 0.81 (95% CI:
0.72–0.90)). The FSS-Per fulfilled a high internal consistency and construct validity to measure the severity of fatigue in Iranian
IPD patients. These acceptable psychometric properties were reproducible in subgroups of IPD patients regarding different levels
of education, disease severity, sex and age groups.
1. Introduction
Fatigue is one of the most disabling nonmotor symptoms of
Parkinson’s disease (PD) [1]. It has been defined as a feeling
of abnormal and overwhelming tiredness and shortage of
energy, which is distinct from normal tiredness both in
quality and quantity [2]. Because of its multidimensionality
and lack of a universal definition, there are a large number
of questionnaires measuring different aspects of fatigue [3].
However, there is no single multidimensional questionnaire,
validated in patients with PD [3]. Based on a review done
by the International Movement Disorders Society (IMDS),
only a few scales are recommended for measuring fatigue
severity in PD, one of which is the fatigue severity scale (FSS)
[4].
TheFSS is a self-report, one-dimensional scale, whichwas
primarily developed in 1989 for patients with multiple scle-
rosis [5]. This scale does not specifically measure cognitive
fatigue [6] and contains nine brief items, each of which is
graded from 1 (strong disagreement) to 7 (strong agreement)
[5]. Although many studies have previously shown the
clinimetric properties of the FSS in different chronic diseases
[5, 7–11], there are few validation reports in PD. On the other
hand, even though the FSS has been validated in different
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languages, there is no study to use the Persian version of the
scale to assess fatigue in PD. Our study aimed to evaluate the
reliability and validity of the Persian version of the FSS (FSS-
Per) as an instrument to assess fatigue in PD patients.
2. Methods
2.1. Study Setting. BetweenOctober 2011 and September 2012,
a total number of 90 idiopathic Parkinson’s disease (IPD)
patients were consecutively recruited from an outpatient
referral Movement Disorder Clinic in Tehran, Iran. This
cross-sectional study was a collaborative project between
Karolinska Institutet, Stockholm, Sweden, and Iran Univer-
sity of Medical Sciences (IUMS), Tehran, Iran.
2.2. Ethical Issues. The study protocol was approved by
the Ethics Committee of the Firoozgar Clinical Research
Development Center (FCRDC) (affiliated to Iran University
of Medical Sciences) in Tehran, Iran. Each participant was
informed about the aims and objectives of the study before
participation, and the completion of the questionnaire was
voluntary. Furthermore, the identity of research participants
was protected, since the data files were anonymous.
2.3. Patients’ Recruitment and Assessment. Patients were eli-
gible if diagnosis of IPD was confirmed using the United
Kingdom (UK) brain bank criteria [12] after a complete
clinical examination done by one neurologist specialized in
movement disorders. Recruited patients were required to be
35 years or older, and those withmoderate to severe dementia
with the Mini-Mental State Examination (MMSE) [13] of
<24 were excluded from the study. In addition, any patient
with atypical parkinsonian syndromes such as multiple sys-
tem atrophy (MSA), vascular parkinsonism, drug-induced
parkinsonism, and progressive supranuclear palsy (PSP) was
excluded.
Data collection was performed using a series of ques-
tionnaires to assess various aspects of the disease during
the interview session and clinical examination. Basic demo-
graphic information consisted of baseline variables, educa-
tional status, and comorbidities. PD-related characteristics
including disease duration (time passed from diagnosis),
measures of disease severity such as Hoehn and Yahr stage
[14], Schwab and England activity of daily living (ADL) scale
[15], the Unified Parkinson’s Disease Rating Scale (UPDRS)
score [16], and levodopa cumulative daily dosage were also
recorded.
The Hoehn and Yahr staging [14] is a widely used clinical
rating scale, supplanted by the UPDRS, which evaluates the
severity of PD based on motor functional disability and
clinical findings consisting of 5 stages. Stage 0 indicates no
visible symptoms of PD, and 5 shows symptoms on both
sides of the body indicating the PD patients who are unable
to walk. Therefore, a higher stage shows greater levels of
functional disability [14]. The Schwab and England scale
[15] is another global scoring system for assessing a PD
patient’s ability to perform daily activities in terms of speed
and independence through a percentage figure, where 100%
indicates total independence, falling to 0%, which indicates
a state of complete dependence in bed-ridden individuals.
Therefore, higher scores show greater level of independence
[15]. As the most commonly used scale in the clinical
study of PD [17], we also used the UPDRS to assess the
severity of Parkinson’s disease in different aspects including
nonmotor symptoms (part I), motor symptoms (part II),
motor examination (part III), and drug complications (part
IV). The UPDRS is scored from a total of 147 points where
higher scores reflect worsening disability [16].
After clinical assessment, patients answered the Persian
version of the fatigue severity scale (FSS-Per) questionnaire
supervised by a group of trained medical students for clarifi-
cation and to avoid missing information.
2.4. Fatigue Severity Scale (FSS) Questionnaire. The Fatigue
Severity Scale (FSS) is a self-report instrument assessing
the physical aspects of fatigue and their impact on the
patient’s daily function in a variety of medical and neurologic
disorders. It evaluates the impact of fatigue on motiva-
tion, exercise, physical functioning, carrying out duties and
responsibilities, and interfering with work, family, or social
life. It contains nine items in the format of brief and under-
standable statements. Patients were asked to rate their level
of fatigue during the past week using a seven-grade Likert
scale. The rating scores range from 1 to 7 for each statement;
however, only the respective ends of the scale are defined
where a low value of 1 indicates “completely disagree” with the
statement and a high value of 7 indicates “completely agree”
or the most severe fatigue. The total FSS score represents
the mean score of the nine items ranging between 1 and
7 where the higher scores indicate more severe fatigue
[5].
The FSS questionnaire was previously translated into Per-
sian language and showed acceptable validity and reliability
among patients with multiple sclerosis [18]. In this project,
we used this Persian-translated version of the FSS (FSS-Per)
in IPD patients.
2.5. Statistical Analysis
2.5.1. Description. Data were analyzed by SPSS software ver-
sion 17.0 (Chicago, IL, USA). In order to describe continuous
and qualitative variables,mean (standard deviation (SD)) and
frequency (percentage) were used, respectively. The mini-
mum, maximum, and coefficient of variation (CV) were also
reported for each of the items in FSS-Per questionnaire. The
principal components analysis (factor analysis) was applied
to explore the best fitted factors with an eigenvalue of >1 to
detect the structure of the FSS.
2.5.2. Reliability. Internal consistency was checked using the
Spearman correlation statistic where mean score of each
item was correlated with the sum of the FSS-Per score.
Furthermore, Cronbach’s alpha intraclass coefficient and the
95% confidence interval (CI) of the point estimations were
calculated for the whole questionnaire and within different
subgroups of IPD patients.
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2.5.3. Validity. Spearman correlationwas used to evaluate the
convergent validity of the total score of the FSS-Per question-
naire in association with the baseline and PD-related vari-
ables. To check the construct validity, the receiver operating
characteristics (ROC) curve statistic was applied to assess
whether the total score of the FSS-Per could discriminate
IPD patients with more severe disease. For this purpose,
IPD patients were divided into two groups: more severe
disability (Hoehn andYahr stage>2) versus less severe disease
(Hoehn and Yahr stage ≤2). The area under curve (AUC)
and its corresponding 95% CI were calculated. Thereafter, a
cut-off value was selected where the best diagnostic indices
(sensitivity and specificity) were met.
In all analytical procedures, a two-sided 𝑃 value <0.05
was considered as the statistical significant level to reject the
beyond H0 hypothesis.
3. Results
3.1. Baseline Characteristics. Study samples consisted of 62
(68.9%) male and 28 (31.1%) female patients with the mean
age of 62.0 (SD = 10.7) years ranging between 38 and 91 years
and the median PD duration of 5.0 years. The majority of
patients were in the mild to moderate stage of PD where
70% (63 out of 90) had the Hoehn and Yahr stage of ≤2 with
the mean UPDRS score of 32.5 (SD = 18.3). Other baseline,
sociodemographic, and clinical characteristics of the patients
are shown in Table 1.
3.2. FSS-Per Structural Characteristics. As it is shown in
Table 2, the mean of the total FSS score was 4.4 (SD = 2.0)
ranging between 1 and 7 in Iranian PD patients. The 4th
item on “the interfering of fatigue with physical functioning”
showed the highest score (4.9 (SD = 2.1)), whereas the last
item on “the interfering of fatigue with work, family and social
life” had the lowest severity score (3.8 (SD = 2.3)). The largest
and smallest coefficient of variation (CV) was also observed
in items 9 (60.5%) and 4 (42.9%), respectively.
In the principal components analysis, the first explored
component of the FSS extracted 76.7% of the common
variance with an eigenvalue of 6.9. However, the eigenvalues
dramatically dropped for the next factors and failed to attain
value above 1.0. The second factor had an eigenvalue of 0.53
indicating that a one-factor structure is the most appropriate
one for the FSS-Per in IPD patients.
3.3. FSS-Per Reliability. As shown in Table 2, the Spearman
Rho was larger than 0.8 for all of the items (all 𝑃 values
<0.001). The highest correlation coefficients were calculated
for the 5th (𝑟 = 0.935) and 6th (𝑟 = 0.932) items, respectively,
while the 1st (𝑟 = 0.803) and 3rd (𝑟 = 0.827) items showed
the lowest internal consistency.
The whole FSS-Per questionnaire had statistically signif-
icant reliability with the Cronbach’s alpha coefficient of 0.961
(95% CI: 0.948–0.972, 𝑃 < 0.001). Figure 1 illustrates the
predicted changes in the reliability index of the FSS-Per ques-
tionnaire if any of the single items were deleted. In general,
the combination of all 9 items showed the highest reliability
Table 1: Baseline, clinical, and sociodemographic characteristics of
the Parkinson’s disease patients (𝑛 = 90).
Characteristics Value
Age (yr)
Mean (SD) 62.0 (10.7)
Gender number (%)
Female 28 (31.1)
Male 62 (68.9)
Level of education number (%)
Illiterate 4 (4.5)
Primary and/or secondary 22 (24.7)
High school/diploma 28 (31.5)
College and/or university 35 (39.3)
Duration of disease (yr)
Mean (SD) 6.0 (4.8)
Comorbidities number (%)
Depression 22 (24.4)
Hypertension 13 (14.4)
Cardiovascular disease 13 (14.4)
Diabetes 13 (14.4)
Osteoarthritis 8 (8.9)
UPDRS score
Mean (SD)
Part I-mental 1.9 (2.3)
Part II-ADL 11.5 (7.3)
Part III-motor 15.4 (9.5)
Part IV-complications 3.7 (2.8)
Total 32.5 (18.3)
Hoehn and Yahr stage
Mean (SD) 1.9 (0.9)
Schwab and England activities of daily living
score (%)
Mean (SD) 81.9 (16.7)
Daily levodopa dose (mg)
Mean (SD) 809 (484)
where the deletion of none of the items increased the total
Cronbach’s alpha coefficient.Moreover, the exclusion of items
5 and 6 demonstrated the highest decrease in the reliability of
the FSS-Per questionnaire, while the absence of the items 1
and 3 had the smallest effect on the Cronbach’s alpha coeffi-
cient. Further analysis resulted inCronbach’s alpha coefficient
of larger than 0.9 in all of the subgroups regarding age,
sex, educational level, and PD severity (all 𝑃 value <0.001).
However, based on the subgroups’ specific 95% CIs, the ques-
tionnaire had significantly higher Cronbach’s alpha among
themales (0.966 (95%CI: 0.952–0.978) versus 0.929 (95%CI:
0.882–0.963)) and higher educated PD patients (0.980 (95%
CI: 0.969–0.989) versus 0.942 (95% CI: 0.916–0.963)).
3.4. FSS-Per Validity. As shown in Table 3, PD duration and
severity were significantly correlated with the FSS-Per score.
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Table 2: Descriptive characteristics and the Spearman correlation of each item for internal consistency of the FSS questionnaire in Iranian
Parkinson’s disease patients (𝑛 = 90).
Item Mean SD. CV. Spearman Rho Corrected item/total correlation
Item 1
My motivation is lower when I am fatigued 4.6 2.3 50 0.803 0.760
Item 2
Exercise brings on my fatigue 4.6 2.2 47.8 0.865 0.816
Item 3
I am easily fatigued 4.2 2.4 57.1 0.827 0.760
Item 4
Fatigue interferes with my physical
functioning
4.9 2.1 42.9 0.897 0.852
Item 5
Fatigue causes frequent problems for me 4.1 2.4 58.5 0.935 0.922
Item 6
My fatigue prevents sustained physical
functioning
4.4 2.3 52.3 0.932 0.921
Item 7
Fatigue interferes with carrying out certain
duties and responsibilities
4.2 2.2 52.4 0.910 0.893
Item 8
Fatigue is amongst my three most disabling
symptoms
4.4 2.4 54.5 0.851 0.830
Item 9
Fatigue interferes with my work, family, or
social life
3.8 2.3 60.5 0.848 0.799
Total score 4.4 2.0 45.4 — —
SD.: standard deviation; CV.: coefficient of variation.
0.948 0.95 0.952 0.954 0.956 0.958 0.96 0.962
Item 1
Item 2
Item 3
Item 4
Item 5
Item 6
Item 7
Item 8
Item 9
Cronbach’s 𝛼 reliability
Figure 1: Changes in the reliability index (Cronbach’s 𝛼) after
deletion of each single item of the FSS questionnaire in Iranian
Parkinson’s disease patients (𝑛 = 90) (the dotted line represents total
Cronbach’s 𝛼 of the questionnaire (0.961)).
Besides all of the domains of the UPDRS, its total score was
directly correlated with fatigue severity (𝑟 = 0.548, 𝑃 <
0.001). The “Hoehn and Yahr” stage (𝑟 = 0.478, 𝑃 < 0.001)
and the “Schwab and England” ADL scale (𝑟 = −0.487, 𝑃 <
0.001) were also significantly correlated with the total score
of the FSS-Per questionnaire.
Figure 2 illustrates the result of the ROC analysis where
the total score of the FSS-Per questionnaire has significant
Table 3: The Spearman correlation to evaluate the convergent
validity of the FSS questionnaire in association with the baseline
and disease-related variables in Iranian Parkinson’s disease patients
(𝑛 = 90).
Scale/variable Spearman Rho 𝑃 value
Age −0.070 0.512
Duration of disease 0.284 0.007∗
UPDRS Score
Part I-mental 0.264 0.012∗
Part II-ADL 0.519 <0.001∗
Part III-motor 0.521 <0.001∗
Part IV-complications 0.231 0.029∗
Total 0.548 <0.001∗
Hoehn and Yahr stage 0.478 <0.001∗
Schwab and England ADL scale −0.487 <0.001∗
Daily levodopa dose 0.128 0.233
∗Statistical significant correlation (𝑃 < 0.05).
value to discriminate IPD patients withmore severe disability
(Hoehn and Yahr stage >2) versus those with less severe
disease (Hoehn and Yahr stage ≤2) (AUC = 0.81 (95% CI:
0.72–0.90); 𝑃 < 0.001). The cut-off value of 4.5 for the mean
of the total FSS score showed the best diagnostic value for this
discrimination with 92.6% sensitivity and 61.9% specificity.
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Table 4: Trans-cultural reliability and validity of the different language versions of the FSS questionnaire in Parkinson’s disease patients.
Study group Year Language
Reliability Validity
Internal
consistency
(Spearman R)
Internal
consistency
(Cronbach’s 𝛼)
Correlation
coefficient
(UPDRS)
Correlation
coefficient
(Hoehn and
Yahr)
Hagell et al. [19] 2006 Swedish — 0.94 — —
Grace et al. [20] 2007 English 0.44–0.78 0.91 — —
Valderramas et al. [21] 2012 Brazilian-Portuguese — 0.95 0.45 0.40
Current study 2013 Persian 0.76–0.92 0.96 0.55 0.48
Se
ns
iti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
0.0 0.2 0.4 0.6 0.8 1.0
1 − specificity
Figure 2: Receiver operating characteristics (ROC) curve for the
total score of the FSS-Per questionnaire to discriminate Parkinson’s
disease patients with more severe disability with Hoehn and Yahr
stage >2 (area under curve (AUC) = 0.81, 𝑃 < 0.001).
4. Discussion
Our study is one of the first attempts to use the Persian-
translated FSS questionnaire in Iranian Parkinson’s disease
patients in order to evaluate their fatigue. For this purpose,
trans-cultural validation of the instrument is a matter of the
utmost importance. Based on the reliability analysis, the FSS-
Per showed an acceptable internal consistency (correlation
𝑟 > 0.75 in all items) and a very high intraclass correlation
(overall Cronbach’s 𝛼 = 0.96). In addition, the validity of the
FSS-Perwas approved in IPDpatients bymeans of correlation
with the measures of disease severity and discriminative
ability to detect more severe disability.
Table 4 summarizes the few similar reports to evaluate
the psychometric properties of the FSS in PD patients with
different native languages. Similar to our study, a very high
reliability has been shown in all of these studies with a
Cronbach’s alpha coefficient ranging from0.91 to 0.95 [19–21].
Hagell et al. [19] performed a psychometric study on the
Swedish version of the FSS in 118 consecutive PD patients
with all five Hoehn and Yahr stages of disease severity.
They demonstrated that the Swedish-translated FSS had
an excellent reliability based on Cronbach’s alpha of 0.94
[19]. More similar to our findings, the Brazilian-Portuguese
translation of the FSS had shown a Cronbach’s alpha of 0.95
in a sample of 30 PD patients [21]. In another study done
by Grace et al. [20], an acceptable internal consistency of
the English version of the FSS was demonstrated by a split
half reliability of 0.86 and 0.91 in 50 PD patients. They also
showed the interitem correlations between 0.27 and 0.78
for the FSS in PD patients [20]. We observed even higher
internal consistency in the correlations between each single
item and sum of the scores of the entire FSS ranged from 0.76
to 0.92. However, the first item on the patients’ motivation
showed the lowest coherence in the item-total correlation
in our study on PD patients. This finding is in line with a
previous report on the Norwegian-translated version of the
FSS in general population where item 1 showed the lowest
average correlation with the rest of the items and the total
score [22]. Using the Rasch statistical method, Hagell et al.
[19] also found that item 1 did not meet unidimensionality
criteria with other items in the FSS. Nevertheless, exploratory
factor analysis supported the unidimensionality of the entire
scale in PD [19], which is similar to our report on the FSS-Per.
Regarding the construct validity of the FSS-Per, our data
showed moderate to strong correlation between the total
score of the FSS and indices of PD severity such asHoehn and
Yahr Stage, Schwab andEnglandADLScale, and totalUPDRS
score. Recently, Valderramas et al. [21] and Herlofson and
Larsen [23] showed significant correlations between the total
score of the FSS and Hoehn and Yahr and UPDRS scores in
Brazilian and Norwegian IPD patients, respectively. Similar
to our report, both of these previous studies showed a higher
correlation with the total UPDRS score where the nonmotor
symptoms are also considered to estimate PD severity. This
attributes to the important role of the nonmotor symptoms
in fatigue complaints among PD patients [24].
In addition to correlation assessments, we also performed
ROC analysis to evaluate the validity of the FSS scores in
IPD patients. Our findings indicated that the entire FSS score
significantly discriminates between more severe disability
and the IPD patients with less severe stages in term of Hoehn
and Yahr staging. This finding provides more evidence to
support the validity of the FSS in IPD patients. Although this
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discriminative ability of the FSS has been previously shown
to distinguish between diseased and normal population [11,
25–27], our study is one of the first reports to show this
discrimination between more and less severe PD using the
FSS scores.
In our study, further subgroup investigation demon-
strated that the FSS-Per could be used as a reliable fatigue-
specific scale in IPD patients with different age group, sex,
educational level, and disease severity. Statistical analysis
showed acceptable reliability indices even among the older
and less educated IPD patients. In the same way but based
on different statistical methods, Hagell et al. [19] yielded
significant item calibration for the FSS in subsets of PD
patients regarding sex and age groups.
Our study was designed as a cross-sectional project. This
lack of temporality leads to some limitations. It was not possi-
ble to evaluate the validity of the FSS-Per to measure changes
in fatigue during the course of PD. Although our study
covered IPD patients with different level of disease severity,
there was skewness toward less severe stages, and enrollment
criteria excluded patients with clinically significant cognitive
impairment. This selection bias limits the generalisability of
results; however, themain objective of our study was to assess
the psychometric properties of the FSS-Per andnot to provide
a representative picture of fatigue in IPD.
In conclusion, our study demonstrates that the Persian-
translated version of the FSS fulfills the criteria of a reliable
and valid assessment tool to rate the severity of fatigue in IPD
patients. This scale showed good psychometric properties in
IPD patients with different levels of education, disease sever-
ity, and sex and age groups.The high internal consistency and
construct validity support the application of the FSS as an
easy-administered tool to evaluate fatigue in IPD patients.
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